As of 2025-05-31, the EV/EBITDA ratio of NeuBase Therapeutics Inc (NBSE) is -. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NBSE's latest enterprise value is -11.15 mil USD. NBSE's TTM EBITDA according to its financial statements is - mil USD. Dividing these 2 quantities gives us the above NBSE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative Enterprise Value.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |